175 related articles for article (PubMed ID: 15818532)
21. Pemetrexed in malignant pleural mesothelioma.
Gatzemeier U
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
[TBL] [Abstract][Full Text] [Related]
22. Pemetrexed in advanced NSCLC: a review of the clinical data.
Zinner RG; Fossella FV; Herbst RS
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):54-62. PubMed ID: 15339061
[TBL] [Abstract][Full Text] [Related]
23. ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer.
Novello S; le Chevalier T
Lung Cancer; 2001 Dec; 34 Suppl 4():S107-9. PubMed ID: 11742713
[TBL] [Abstract][Full Text] [Related]
24. Pemetrexed for treatment of advanced non-small cell lung cancer.
Fossella FV
Semin Oncol; 2004 Feb; 31(1 Suppl 1):100-5. PubMed ID: 14981587
[TBL] [Abstract][Full Text] [Related]
25. Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data.
Zinner RG; Herbst RS
Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S67-74. PubMed ID: 15117428
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed disodium.
Gibbs D; Jackman A
Nat Rev Drug Discov; 2005 May; Suppl():S16-7. PubMed ID: 15962527
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
[TBL] [Abstract][Full Text] [Related]
28. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
Scagliotti GV
Lung Cancer; 2005 Oct; 50 Suppl 1():S18-9. PubMed ID: 16291426
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed for diffuse malignant pleural mesothelioma.
Manegold C; Aisner J
Semin Oncol; 2002 Apr; 29(2 Suppl 5):30-5. PubMed ID: 12023790
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed and its emerging role in the treatment of thoracic malignancies.
Scagliotti GV; Novello S
Expert Opin Investig Drugs; 2003 May; 12(5):853-63. PubMed ID: 12720495
[TBL] [Abstract][Full Text] [Related]
31. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
Jalal S; Ansari R; Govindan R; Bhatia S; Bruetman D; Fisher W; Masters G; White A; Stover D; Yu M; Hanna N;
J Thorac Oncol; 2009 Jan; 4(1):93-6. PubMed ID: 19096313
[TBL] [Abstract][Full Text] [Related]
32. Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesothelioma.
Green MR
Lung Cancer; 2002 Nov; 38 Suppl 2():S55-7. PubMed ID: 12431831
[TBL] [Abstract][Full Text] [Related]
33. Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
Calvert H
Semin Oncol; 2003 Apr; 30(2 Suppl 3):2-5. PubMed ID: 12722017
[TBL] [Abstract][Full Text] [Related]
34. Phase I trials of pemetrexed.
Fossella FV; Gatzemeier U
Semin Oncol; 2002 Apr; 29(2 Suppl 5):8-16. PubMed ID: 12023787
[TBL] [Abstract][Full Text] [Related]
35. Pemetrexed: an active new agent for breast cancer.
O'Shaughnessy JA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):57-62. PubMed ID: 12571813
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed in the treatment of selected solid tumors.
Adjei AA
Semin Oncol; 2002 Apr; 29(2 Suppl 5):50-3. PubMed ID: 12023793
[TBL] [Abstract][Full Text] [Related]
37. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
38. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
39. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
40. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
